Johnson & Johnson
Preço: 240.87Empresa e modelo de negócios
Johnson & Johnson is a global healthcare company that develops and manufactures a wide range of products across three major segments: Pharmaceuticals, Medical Devices, and Consumer Health. Its core products include prescription medications, surgical instruments, and consumer health products such as over-the-counter drugs and personal care items. The company generates revenue primarily from its pharmaceutical segment, which includes treatments for various diseases, followed by medical devices and consumer health products.
Perfil de investimento
Johnson & Johnson presents a balanced investment profile, appealing to investors seeking a combination of growth and dividends. The company has a stable dividend yield, indicating a commitment to returning value to shareholders. Its diversified business segments provide resilience against market fluctuations, making it suitable for medium to long-term investment horizons.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- 8.67 OK
- Receita QoQ — crescimento da receita trimestre contra trimestre
- -2.0% ↓
- Surpresa de EPS
- 0.7% em linha
- Volatilidade 20d
- 1.2% estável
- Dividend yield
- 2.3% moderado última data ex-dividendo: 2026-05-26
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-10 00:46 | Manter | Comprar | Strong momentum and solid dividend yield support growth. |
| 2026-05-30 02:42 | Comprar | Manter | Weak momentum and fundamentals raise uncertainty. |
| 2026-05-22 02:50 | Manter | Comprar | Stable dividends, but mixed momentum signals present uncertainty. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-05-13 10:04 | Leerink Partners | Rating elevado | — → 265 | 224.26 |
| 2026-04-20 12:24 | Guggenheim | Preço-alvo elevado | 244 → 266 | 232.71 |
| 2026-04-15 12:31 | Morgan Stanley | Preço-alvo elevado | 267 → 283 | 239.66 |